Phase
Condition
Ankylosing Spondylitis
Treatment
Placebo
608
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Female and male patients at least 18 years of age at the time of screening.
Diagnosis of axial spondyloarthritis according to Ankylosing Spondylo ArthritisInternational Society (ASAS) axial spondyloarthritis criteria
Objective signs of inflammation (magnetic resonance imaging (MRI) or abnormalC-reactive protein)
Total back pain as measured by NRS ≥ 4 at baseline
Exclusion
Exclusion Criteria:
Patients with other uncontrolled active inflammatory diseases.
Clinical laboratory tests and other tests that reveal abnormalities with clinicalsignificance
Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined bypositive results at Screening.
History of cancer.
Known or suspected history of immunosuppression.
Known with allergic or intolerant to mometasone furoate spray or 608/placebo.
Study Design
Study Description
Connect with a study center
Site 01
Beijing, Beijing 100730
ChinaActive - Recruiting
Site 03
Beijing, Beijing 100730
ChinaActive - Recruiting
Site 05
Chongqing, Chongqing 400010
ChinaActive - Recruiting
Site 02
Zhengzhou, Henan 450052
ChinaActive - Recruiting
Site 04
Nanjing, Jiangsu 210008
ChinaActive - Recruiting
Site 06
Shenzhen, Shenzhen 518020
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.